NCT03018652 - Feasibility and Safety of Immunoglobulin (Ig) Treatment in COPD Outpatients With Frequent Exacerbations: Pilot Study 1 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 11, 2018

Primary Completion Date

November 20, 2019

Study Completion Date

November 20, 2019

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG

Intravenous immunoglobulin

IVIG 0.5 g/kg, up to maximum of 80 grams will be given on the day of randomization and then every 4 ± 1 weeks for 44 weeks (Total 48 weeks)

DRUG

Normal Saline

5 mL/kg, up to maximum of 800 mL will be given on the day of randomization (this will match the volume of 0.5g/kg of IVIG product) and then every 4 ± 1 weeks for 44 weeks (Total 48 weeks)

Trial Locations (1)

K1J 0J2

The Ottawa Hospital, General Campus, Ottawa